LAWSUITS FILED AGAINST DKNG, QFIN and ITRM - Jakubowitz Law Pursues Shareholders Claims
Back to Newsroom
Mentioned in this Article

LAWSUITS FILED AGAINST DKNG, QFIN and ITRM - Jakubowitz Law Pursues Shareholders Claims

Tuesday, August 31, 2021 11:30 AM
Share this article now
Topic:
Lawsuits
Jakubowitz Law

NEW YORK, NY / ACCESSWIRE / August 31, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. (NASDAQ:DKNG)

CONTACT JAKUBOWITZ ABOUT DKNG:
https://claimyourloss.com/securities/draftkings-inc-f-k-a-diamond-eagle-acquisition-corp-loss-submission-form/?id=19172&from=1

Class Period : December 23, 2019 - June 15, 2021

Lead Plaintiff Deadline : August 31, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) SBTech Global Limited ("SBTech"), a company acquired by DraftKings, had a history of unlawful operations; (ii) accordingly, DraftKings' merger with SBTech exposed the Company to dealings in black-market gaming; (iii) the foregoing increased the Company's regulatory and criminal risks with respect to these transactions; (iv) as a result of all the foregoing, the Company's revenues were, in part, derived from unlawful conduct and thus unsustainable; (v) accordingly, the benefits of the Business Combination were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

360 DigiTech, Inc. (NASDAQ:QFIN)

CONTACT JAKUBOWITZ ABOUT QFIN:
https://claimyourloss.com/securities/360-digitech-inc-loss-submission-form/?id=19172&from=1

Class Period : April 29, 2021 - July 7, 2021

Lead Plaintiff Deadline : September 13, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had been collecting personal information in violation of relevant People's Republic of China laws and regulations; (ii) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Iterum Therapeutics Plc (NASDAQ:ITRM)

CONTACT JAKUBOWITZ ABOUT ITRM:
https://claimyourloss.com/securities/iterum-therapeutics-plc-loss-submission-form/?id=19172&from=1

Class Period : November 30, 2020 - July 23, 2021

Lead Plaintiff Deadline : October 4, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law
 

Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions